Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. German Breast Group, Frankfurt, Germany

Survival: 11.7 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Germany
City/State/Province: Frankfurt
Hospital: German Breast Group
Journal: Link
Date: 1/2005

Patients: This Phase II study involved 58 women with metastatic breast cancer. The mean age was 54.2 years. Metastatic sites included liver, bone lung, and lymph nodes. All patients had previously received anthracycline and taxane treatment before this study.

Treatment: The treatment consisted of one chemotherapeutic agent: gefitinib.

Toxicity: Grade 3-4 toxicities included: diarrhea,, dry skin, rash, nausea, exanthema, and fatigue.

Results: The median overall survival was 11.7 months (357 days). The authors concluded that although the drug was well tolerated, "Gefitinib failed to show any benefit in terms of response rate or disease control in this population."

Support: AstraZeneca, Germany, supported this study. AstraZeneca develops, manufactures, and markets gefitinib.

Correspondence: Gunter von Minckwitz, MD

E-mail to a Friend Email Physician More Information